Cargando…

The Status of p53 Oligomeric and Aggregation States in Cancer

Despite being referred to as the guardian of the genome, when impacted by mutations, p53 can lose its protective functions and become a renegade. The malignant transformation of p53 occurs on multiple levels, such as altered DNA binding properties, acquisition of novel cellular partners, or associat...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Oliveira, Guilherme A. P., Petronilho, Elaine C., Pedrote, Murilo M., Marques, Mayra A., Vieira, Tuane C. R. G., Cino, Elio A., Silva, Jerson L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226498/ https://www.ncbi.nlm.nih.gov/pubmed/32260447 http://dx.doi.org/10.3390/biom10040548

Ejemplares similares

Aggregation tendencies in the p53 family are modulated by backbone hydrogen bonds
por: Cino, Elio A., et al.
Publicado: (2016)

Phase separation of p53 precedes aggregation and is affected by oncogenic mutations and ligands
por: Petronilho, Elaine C., et al.
Publicado: (2021)

Aggregation-primed molten globule conformers of the p53 core domain provide potential tools for studying p53C aggregation in cancer
por: Pedrote, Murilo M., et al.
Publicado: (2018)

The aggregation of mutant p53 produces prion-like properties in cancer
por: Rangel, Luciana P, et al.
Publicado: (2014)

Loss of the p53 transactivation domain results in high amyloid aggregation of the Δ40p53 isoform in endometrial carcinoma cells
por: Melo dos Santos, Nataly, et al.
Publicado: (2019)

Protein of a thousand faces: The tumor-suppressive and oncogenic responses of p53
por: Marques, Mayra A., et al.
Publicado: (2022)

Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer
por: de Oliveira, Guilherme A. P., et al.
Publicado: (2015)

Oncogenic Gain of Function in Glioblastoma Is Linked to Mutant p53 Amyloid Oligomers
por: Pedrote, Murilo M., et al.
Publicado: (2020)

Rabbit PrP Is Partially Resistant to in vitro Aggregation Induced by Different Biological Cofactors
por: Angelli, Juliana N., et al.
Publicado: (2021)

Alpha-synuclein stepwise aggregation reveals features of an early onset mutation in Parkinson’s disease
por: de Oliveira, Guilherme A. P., et al.
Publicado: (2019)

The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation
por: Lázaro, Diana F., et al.
Publicado: (2016)

Anticancer Therapeutic Strategies Targeting p53 Aggregation
por: Ferretti, Giulia D. S., et al.
Publicado: (2022)

Prion Protein Complexed to N2a Cellular RNAs through Its N-terminal Domain Forms Aggregates and Is Toxic to Murine Neuroblastoma Cells
por: Gomes, Mariana P. B., et al.
Publicado: (2008)

Mutant p53 Aggregates into Prion-like Amyloid Oligomers and Fibrils: IMPLICATIONS FOR CANCER
por: Ano Bom, Ana P. D., et al.
Publicado: (2012)

Resveratrol prevents p53 aggregation in vitro and in breast cancer cells
por: Ferraz da Costa, Danielly C., et al.
Publicado: (2018)

Anomalous structural dynamics of minimally frustrated residues in cardiac troponin C triggers hypertrophic cardiomyopathy
por: Marques, Mayra A., et al.
Publicado: (2021)

Potential enhancement of post-stroke angiogenic response by targeting the oligomeric aggregation of p53 protein
por: Tam, Hoi Hei, et al.
Publicado: (2023)

Ligand Binding and Hydration in Protein Misfolding: Insights from Studies of Prion and p53 Tumor Suppressor Proteins
por: Silva, Jerson L., et al.
Publicado: (2009)

Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor
por: Silva, Jerson L., et al.
Publicado: (2013)

p53 oligomerization status as an indicator of sensitivity of p53-wildtype neuroblastomas to the combination of DNA damaging agent and Chk1 inhibitor
por: Levesque, Aime A., et al.
Publicado: (2022)

Characterization of the Oligomerization and Aggregation of Human Serum Amyloid A
por: Patke, Sanket, et al.
Publicado: (2013)

Infrared nanospectroscopy characterization of oligomeric and fibrillar aggregates during amyloid formation
por: Ruggeri, F. S., et al.
Publicado: (2015)

PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma
por: Paz, Mariana M., et al.
Publicado: (2023)

Hydroxytyrosol Inhibits Protein Oligomerization and Amyloid Aggregation in Human Insulin
por: Sirangelo, Ivana, et al.
Publicado: (2020)

Probing the Origin of the Toxicity of Oligomeric Aggregates of α-Synuclein with Antibodies
por: Cascella, Roberta, et al.
Publicado: (2019)

Oligomerization of Selective Autophagy Receptors for the Targeting and Degradation of Protein Aggregates
por: Chen, Wenjun, et al.
Publicado: (2021)

Systematic Comparison of the Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation
por: Lázaro, Diana F., et al.
Publicado: (2014)

Electrostatics Drive Oligomerization and Aggregation of Human Interferon Alpha-2a
por: Pohl, Christin, et al.
Publicado: (2021)

Inhibition of IAPP aggregation by insulin depends on the insulin oligomeric state regulated by zinc ion concentration
por: Nedumpully-Govindan, Praveen, et al.
Publicado: (2015)

Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD
por: Esteves, A. R., et al.
Publicado: (2011)

p53 Aggregates Penetrate Cells and Induce the Co-Aggregation of Intracellular p53
por: Forget, Karolyn J., et al.
Publicado: (2013)

A Generic Mechanism of Emergence of Amyloid Protofilaments from Disordered Oligomeric Aggregates
por: Auer, Stefan, et al.
Publicado: (2008)

The Role of Alpha-Synuclein Oligomerization and Aggregation in Cellular and Animal Models of Parkinson’s Disease
por: Wan, Oi Wan, et al.
Publicado: (2012)

Confocal Spectroscopy to Study Dimerization, Oligomerization and Aggregation of Proteins: A Practical Guide
por: Gambin, Yann, et al.
Publicado: (2016)

Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein
por: Reimer, Lasse, et al.
Publicado: (2022)

Oligomeric procyanidins inhibit insulin fibrillation by forming unstructured and off-pathway aggregates
por: Chen, Shaohuang, et al.
Publicado: (2021)

Loss of TDP‐43 oligomerization or RNA binding elicits distinct aggregation patterns
por: Pérez‐Berlanga, Manuela, et al.
Publicado: (2023)

Early proteostasis of caveolins synchronizes trafficking, degradation, and oligomerization to prevent toxic aggregation
por: Morales-Paytuví, Frederic, et al.
Publicado: (2023)

AHNAK controls 53BP1-mediated p53 response by restraining 53BP1 oligomerization and phase separation
por: Ghodke, Indrajeet, et al.
Publicado: (2021)

Cancer Chemoprevention by Resveratrol: The p53 Tumor Suppressor Protein as a Promising Molecular Target
por: Ferraz da Costa, Danielly C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eqm9rllmfabvqemp154qrfjjn6